Skip to main content
Erschienen in: Journal of General Internal Medicine 4/2019

08.08.2018 | Original Research

Randomized Trial of Personalized Breast Density and Breast Cancer Risk Notification

verfasst von: Jennifer S. Haas, MD, MSc, Catherine S. Giess, MD, Kimberly A. Harris, MM, Julia Ansolabehere, Celia P. Kaplan, DrPh, MA

Erschienen in: Journal of General Internal Medicine | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite widespread implementation of mammographic breast density (MBD) notification laws, the impact of these laws on knowledge of MBD and knowledge of breast cancer risk is limited by the lack of tools to promote informed decision-making in practice.

Objective

To develop and evaluate whether brief, personalized informational videos following a normal mammogram in addition to a legislatively required letter about MBD result can improve knowledge of MBD and breast cancer risk compared to standard care (i.e., legislatively required letter about MBD included with the mammogram result).

Design/Participants

Prospective randomized controlled trial of English-speaking women, age 40–74 years, without prior history of breast cancer, receiving a screening mammogram with a normal or benign finding (intervention group n = 235, control group n = 224). Intervention: brief (3–5 min) video, personalized to a woman’s MBD result and breast cancer risk.

Main Measures

Primary outcomes were a woman’s knowledge of her MBD and risk of breast cancer. Secondary outcomes included whether a woman reported that she discussed the results of her mammogram with her primary care provider (PCP).

Key Results

Relative to women in the control arm, women in the intervention arm had greater improvement in their knowledge of both their personal MBD (intervention pre/post 39.2%/ 77.5%; control pre/post 36.2%/ 37.5%; odds ratio (OR) 5.34 for change for intervention vs. control, 95% confidence interval (CI) 3.87–7.36; p < 0.001) and risk of breast cancer (intervention pre/post: 66.8%/74.0%; control pre/post 67.9%/ 65.2%; OR 1.42, 95% confidence interval (CI) 1.09–1.84; p = 0.01). Women in the intervention group were more likely than those in the control group to report discussing the results of their mammogram with their PCP (p = 0.05).

Conclusions

Brief, personalized videos following mammography can improve knowledge of MBD and personal risk of breast cancer compared to a legislatively mandated informational letter.
Trial Registration
Clinicaltrials.​gov (NCT02986360)
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Smith RA, Kerlikowske K, Miglioretti DL, Kalager M. Clinical decisions. Mammography screening for breast cancer. N Engl J Med 2012;367:e31.CrossRefPubMed Smith RA, Kerlikowske K, Miglioretti DL, Kalager M. Clinical decisions. Mammography screening for breast cancer. N Engl J Med 2012;367:e31.CrossRefPubMed
2.
Zurück zum Zitat Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL, Breast Cancer Surveillance C. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med 2015;162:673–81.CrossRefPubMedPubMedCentral Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL, Breast Cancer Surveillance C. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med 2015;162:673–81.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Porter GJ, Evans AJ, Cornford EJ, Burrell HC, James JJ, Lee AH, Chakrabarti J. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 2007;188:676–83.CrossRefPubMed Porter GJ, Evans AJ, Cornford EJ, Burrell HC, James JJ, Lee AH, Chakrabarti J. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 2007;188:676–83.CrossRefPubMed
4.
Zurück zum Zitat Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, Wernli KJ, Miglioretti DL, O'Meara ES. Outcomes of Screening Mammography by Frequency, Breast Density, and Postmenopausal Hormone Therapy. JAMA Intern Med 2013:1–10. Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, Wernli KJ, Miglioretti DL, O'Meara ES. Outcomes of Screening Mammography by Frequency, Breast Density, and Postmenopausal Hormone Therapy. JAMA Intern Med 2013:1–10.
7.
Zurück zum Zitat Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014;106. Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014;106.
8.
Zurück zum Zitat Kressin NR, Gunn CM, Battaglia TA. Content, Readability, and Understandability of Dense Breast Notifications by State. JAMA 2016;315:1786–8.CrossRefPubMed Kressin NR, Gunn CM, Battaglia TA. Content, Readability, and Understandability of Dense Breast Notifications by State. JAMA 2016;315:1786–8.CrossRefPubMed
9.
Zurück zum Zitat Santiago-Rivas M, Benjamin S, Jandorf L. Breast Density Knowledge and Awareness: A Review of Literature. J Prim Care Community Health 2016;7:207–14.CrossRefPubMedPubMedCentral Santiago-Rivas M, Benjamin S, Jandorf L. Breast Density Knowledge and Awareness: A Review of Literature. J Prim Care Community Health 2016;7:207–14.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Klinger EV, Kaplan CP, St. Hubert S, Birdwell RL, Haas JS. Patient and Provider Perspectives on Mammographic Breast Density Notification Legislation. MDM Policy & Practice 2017;1:1–8. Klinger EV, Kaplan CP, St. Hubert S, Birdwell RL, Haas JS. Patient and Provider Perspectives on Mammographic Breast Density Notification Legislation. MDM Policy & Practice 2017;1:1–8.
11.
Zurück zum Zitat Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115–22.CrossRefPubMed Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115–22.CrossRefPubMed
12.
Zurück zum Zitat Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337–47.CrossRefPubMedPubMedCentral Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337–47.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol 2015;33:3137–43.CrossRefPubMedPubMedCentral Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol 2015;33:3137–43.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kaplan CP, Livaudais-Toman J, Tice JA, Kerlikowske K, Gregorich SE, Perez-Stable EJ, Pasick RJ, Chen A, Quinn J, Karliner LS. A randomized, controlled trial to increase discussion of breast cancer in primary care. Cancer Epidemiol Biomark Prev 2014;23:1245–53.CrossRef Kaplan CP, Livaudais-Toman J, Tice JA, Kerlikowske K, Gregorich SE, Perez-Stable EJ, Pasick RJ, Chen A, Quinn J, Karliner LS. A randomized, controlled trial to increase discussion of breast cancer in primary care. Cancer Epidemiol Biomark Prev 2014;23:1245–53.CrossRef
15.
Zurück zum Zitat Haas JS, Kaplan CP. The Divide Between Breast Density Notification Laws and Evidence-Based Guidelines for Breast Cancer Screening: Legislating Practice. JAMA Intern Med 2015;175:1439–40.CrossRefPubMedPubMedCentral Haas JS, Kaplan CP. The Divide Between Breast Density Notification Laws and Evidence-Based Guidelines for Breast Cancer Screening: Legislating Practice. JAMA Intern Med 2015;175:1439–40.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Rhodes DJ, Radecki Breitkopf C, Ziegenfuss JY, Jenkins SM, Vachon CM. Awareness of breast density and its impact on breast cancer detection and risk. J Clin Oncol Off J Am Soc Clin Oncol 2015;33:1143–50.CrossRef Rhodes DJ, Radecki Breitkopf C, Ziegenfuss JY, Jenkins SM, Vachon CM. Awareness of breast density and its impact on breast cancer detection and risk. J Clin Oncol Off J Am Soc Clin Oncol 2015;33:1143–50.CrossRef
17.
Zurück zum Zitat Schonberg MA, Hamel MB, Davis RB, Griggs MC, Wee CC, Fagerlin A, Marcantonio ER. Development and evaluation of a decision aid on mammography screening for women 75 years and older. JAMA Intern Med 2014;174:417–24.CrossRefPubMedPubMedCentral Schonberg MA, Hamel MB, Davis RB, Griggs MC, Wee CC, Fagerlin A, Marcantonio ER. Development and evaluation of a decision aid on mammography screening for women 75 years and older. JAMA Intern Med 2014;174:417–24.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Haas JS, Baer HJ, Eibensteiner K, Klinger EV, St Hubert S, Getty G, Brawarsky P, Orav EJ, Onega T, Tosteson AN, Bates DW, Colditz G. A Cluster Randomized Trial of a Personalized Multi-Condition Risk Assessment in Primary Care. Am J Prev Med 2017;52:100–5.CrossRefPubMed Haas JS, Baer HJ, Eibensteiner K, Klinger EV, St Hubert S, Getty G, Brawarsky P, Orav EJ, Onega T, Tosteson AN, Bates DW, Colditz G. A Cluster Randomized Trial of a Personalized Multi-Condition Risk Assessment in Primary Care. Am J Prev Med 2017;52:100–5.CrossRefPubMed
19.
Zurück zum Zitat Knerr S, Wernli KJ, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Luta G, Schwartz MD, O'Neill SC. A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. Contemp Clin Trials 2017;56:25–33.CrossRefPubMedPubMedCentral Knerr S, Wernli KJ, Leppig K, Ehrlich K, Graham AL, Farrell D, Evans C, Luta G, Schwartz MD, O'Neill SC. A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. Contemp Clin Trials 2017;56:25–33.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Moyer VA, for the US Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:698–708.PubMed Moyer VA, for the US Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:698–708.PubMed
Metadaten
Titel
Randomized Trial of Personalized Breast Density and Breast Cancer Risk Notification
verfasst von
Jennifer S. Haas, MD, MSc
Catherine S. Giess, MD
Kimberly A. Harris, MM
Julia Ansolabehere
Celia P. Kaplan, DrPh, MA
Publikationsdatum
08.08.2018
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 4/2019
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-018-4622-4

Weitere Artikel der Ausgabe 4/2019

Journal of General Internal Medicine 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.